eureKARE news & blog

Stellate Therapeutics publishes positive results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101

Stellate Therapeutics Inc. (“the Company”, “Stellate”), a global biotechnology company developing disease-modifying therapies based on molecules derived from the microbiome to treat neurological conditions, is pleased to announce the publication of data evaluating the efficacy of the Company’s microbiome-derived lead candidate, STL-101 (synthesized queuine) in in vitro experiments. The data, published in the peer-reviewed scientific journal PLOS ONE, demonstrate that STL-101 has neuroprotective properties.

NovoBiome labelled French Tech Seed by the AgriO

-NovoBiome announces
that the AgriO Committee has labelled NovoBiome a ‘French Tech Seed’, paving the way for
NovoBiome to receive additional public fund.
-Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: “We are thrilled to have
obtained this recognition by AgriO, which validates the potential of our disruptive ex-vivo
discovery platform. Moreover, it confirms the interest in the field of intestinal microbiota,
witnessing the close links between the two universes of health, and food and nutrition.”

NovoBiome and INRAE, a new Associated Partner Laboratory on human gut microbiota

-New partnership to aggregate cutting-edge technologies to study host-microbiota relationships as closely as possible to human physiology.
-Confirmation of INRAE’s commitment to develop and enhance the excellence of the research carried out by this reference institute

1 2 3 4

Luxembourg

France

Belgium

 

Privacy & Cookies

France – Belgium – Luxembourg

Privacy & Cookies